Browse our anti-PLAUR (PLAUR) Antibodies

Full name:
anti-Plasminogen Activator, Urokinase Receptor Antibodies (PLAUR)
On are 216 Plasminogen Activator, Urokinase Receptor (PLAUR) Antibodies from 26 different suppliers available. Additionally we are shipping PLAUR Kits (60) and PLAUR Proteins (35) and many more products for this protein. A total of 327 PLAUR products are currently listed.
CD87, Par, PLAUR, Plaur3, U-PAR, UPAR, uPAR-2, uPAR-3, URKR
list all antibodies Gene Name GeneID UniProt
PLAUR 18793 P35456
PLAUR 5329 Q03405
PLAUR 50692 P49616

Show all species

Show all synonyms

Most Popular Reactivities for anti-PLAUR (PLAUR) Antibodies

Select your species and application

anti-Mouse (Murine) PLAUR Antibodies:

anti-Human PLAUR Antibodies:

anti-Rat (Rattus) PLAUR Antibodies:

All available anti-PLAUR Antibodies

Go to our pre-filtered search.

Top referenced anti-PLAUR Antibodies

  1. Human Polyclonal PLAUR Primary Antibody for WB - ABIN1944762 : Roldan, Cubellis, Masucci, Behrendt, Lund, Danø, Appella, Blasi: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. in The EMBO journal 1990 (PubMed)
    Show all 5 references for 1944762

  2. Mouse (Murine) Polyclonal PLAUR Primary Antibody for FACS, WB - ABIN4900558 : van Zoelen, Florquin, de Beer, Pater, Verstege, Meijers, van der Poll: Urokinase plasminogen activator receptor-deficient mice demonstrate reduced hyperoxia-induced lung injury. in The American journal of pathology 2009 (PubMed)
    Show all 2 references for 4900558

  3. Human Polyclonal PLAUR Primary Antibody for IP, Neut - ABIN223158 : Viswanathan, Richardson, Togonu-Bickersteth, Dai, Liu, Vatsya, Sun, Yu, Munuswamy-Ramanujam, Baker, Lucas: Myxoma viral serpin, Serp-1, inhibits human monocyte adhesion through regulation of actin-binding protein filamin B. in Journal of leukocyte biology 2009 (PubMed)

More Antibodies against PLAUR Interaction Partners

Mouse (Murine) Plasminogen Activator, Urokinase Receptor (PLAUR) interaction partners

  1. The synergy of circulating factor suPAR and APOL1 (show APOL1 Antibodies) G1 or G2 on alphavbeta3 integrin activation is a mechanism for CKD.

  2. Results identify soluble uPAR as a functional connection between the bone marrow and the kidney, and they implicate bone marrow immature myeloid cells as a key source of soluble uPAR that leads to glomerular dysfunction.

  3. Plaur deficiency does not increase susceptibility to epileptogenesis after traumatic brain injury in an animal model.

  4. Significance of the urokinase-type plasminogen activator (show PLAU Antibodies) and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.

  5. Findings indicate a significant correlation of uPAR cleavage with breast cancer progression, but the precise biological consequence(s) of the cleavage or the cleavage products still remains to be elucidated.

  6. interaction of full-length suPAR with alphavbeta3 integrin expressed on podocytes results in down-modulation of nephrin (show NPHS1 Antibodies) that may affect kidney functionality in different human pathologies characterized by increased concentration of suPAR.

  7. In an in vivo murine angiogenesis model uPAR-deficient PTEN (show PTEN Antibodies) heterozygous animals increased the impaired angiogenic phenotype of uPAR knockout mice and were able to reverse the high invasive potential of PTEN (show PTEN Antibodies) heterozygotes.

  8. uPAR contributes to macrophage driven atherosclerotic lesion formation.

  9. we have firstly shown a fundamental mechanism of urokinase system(uPa (show PLAU Antibodies) and uPAR)-dependent regulation of the trajectory of growth and branching of blood vessels in early embryogenesis and in adults during the repair/regeneration of tissues.

  10. our data show that uPAR is required for efficient skin tumor formation

Human Plasminogen Activator, Urokinase Receptor (PLAUR) interaction partners

  1. The synergy of circulating factor suPAR and APOL1 (show APOL1 Antibodies) G1 or G2 on alphavbeta3 integrin activation is a mechanism for CKD.

  2. Patients with cancer were significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to patients who were not diagnosed with cancer. Previous cancer, C-reactive protein (CRP (show CRP Antibodies)) and suPAR were significantly associated with newly diagnosed cancer during follow-up in multiple logistic regression analyses adjusted for age, sex and CRP (show CRP Antibodies)

  3. This is the first report that PGE2 -induced uPAR expression, which stimulates invasiveness of human gastric cancer AGS (show JAG1 Antibodies) cells, is mediated by the EP2 receptor-dependent Src (show SRC Antibodies)/EGFR (show EGFR Antibodies)/JNK1 (show MAPK8 Antibodies)/2, Erk1/2 (show MAPK1/3 Antibodies)/AP-1 (show FOSB Antibodies), and Src (show SRC Antibodies)/EGFR (show EGFR Antibodies)/JNK1 (show MAPK8 Antibodies)/2, Erk1/2 (show MAPK1/3 Antibodies)/NF-kappaB (show NFKB1 Antibodies) cascades.

  4. Studies indicate the feasibility of combining two U-PA (show PLAU Antibodies) receptor (uPAR)-targeted probes in a preclinical head and neck cancer model.

  5. soluble urokinase plasminogen activator receptor was associated with low left ventricular ejection fraction and elevated BNP (show BNC2 Antibodies).

  6. Results suggest that soluble urokinase-type plasminogen activator receptor levels are positively correlated with severity of acute pancreatitis.

  7. results show that the uPA (show PRAP1 Antibodies)/uPAR/LRP1 (show LRP1 Antibodies) system is a potential target for the development of therapeutic strategies to promote axonal recovery following a CNS injury

  8. our study indicates that suPAR increases in patients with AML (show RUNX1 Antibodies) and this situation is associated with poorer survival. suPAR can thus be used as a diagnostic and prognostic biomarker in AML (show RUNX1 Antibodies) and may help in the developing of specific therapeutic targets.

  9. urokinase plasminogen activator receptor has a role in incidence of venous thromboembolism

  10. Our study implies that both soluble UPAR and advanced echocardiography are useful diagnostic tools for identifying patients with diabetes at risk of future clinical heart disease

Cow (Bovine) Plasminogen Activator, Urokinase Receptor (PLAUR) interaction partners

  1. Data show that urokinase-type plasminogen activator (uPA (show PLAU Antibodies)) is only expressed in the cumulus cells of immature and in vitro matured cumulus-oocyte complexes (COCs), while uPA (show PLAU Antibodies) receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1 (show SERPINE1 Antibodies)) are expressed in both the cumulus cells and the immature and in vitro matured oocytes.

  2. uPA (show PLAU Antibodies)/uPAR binding is involved in signaling pathways that activate transcription factors that regulate the synthesis of molecules concerned with the arrangement of a particular oviductal microenvironment.

  3. Data indicate that superoxide dismutase (SOD) inhibited high glucose (HG)-induced expression of uPAR and VEGF in bovine retinal microvascular endothelial cell (REC).

  4. These data indicated that E. coli LPS (show IRF6 Antibodies) led to an increase in u-PA (show PLAU Antibodies) activity and RNA expression of u-PA (show PLAU Antibodies) and u-PAR in BME-UV1 cells, thus strengthening the role of the PA system during pathological processes.

  5. the interaction between uPAR and Man-6-P/IGF2R (show IGF2R Antibodies) is a low percentage binding event and that suPAR and full-length uPAR bind the Man-6-P/IGF2R (show IGF2R Antibodies) by different mechanisms.

PLAUR Antigen Profile

Antigen Summary

This gene encodes the receptor for urokinase plasminogen activator and, given its role in localizing and promoting plasmin formation, likely influences many normal and pathological processes related to cell-surface plasminogen activation and localized degradation of the extracellular matrix. It binds both the proprotein and mature forms of urokinase plasminogen activator and permits the activation of the receptor-bound pro-enzyme by plasmin. The protein lacks transmembrane or cytoplasmic domains and may be anchored to the plasma membrane by a glycosyl-phosphatidylinositol (GPI) moiety following cleavage of the nascent polypeptide near its carboxy-terminus. However, a soluble protein is also produced in some cell types. Alternative splicing results in multiple transcript variants encoding different isoforms. The proprotein experiences several post-translational cleavage reactions that have not yet been fully defined.

Alternative names and synonyms associated with PLAUR

  • plasminogen activator, urokinase receptor (PLAUR) antibody
  • plasminogen activator, urokinase receptor (Plaur) antibody
  • urokinase-type plasminogen activator receptor (LOC100101584) antibody
  • CD87 antibody
  • Par antibody
  • PLAUR antibody
  • Plaur3 antibody
  • U-PAR antibody
  • UPAR antibody
  • uPAR-2 antibody
  • uPAR-3 antibody
  • URKR antibody

Protein level used designations for PLAUR

urokinase plasminogen activator surface receptor , plasminogen activator, urokinase receptor , urokinase plasminogen activator receptor , urokinase-type plasminogen activator receptor , monocyte activation antigen Mo3 , u-plasminogen activator receptor form 2 , urokinase-type plasminogen activator (uPA) receptor , U-PAR , uPAR , plasminogen activator urokinase receptor 3 , urinary plasminogen activator receptor 2 , urinary plasminogen activator receptor 3

100033904 Equus caballus
100302564 Ovis aries
18793 Mus musculus
5329 Homo sapiens
476446 Canis lupus familiaris
281983 Bos taurus
50692 Rattus norvegicus
450103 Pan troglodytes
100101584 Oryctolagus cuniculus
Selected quality suppliers for anti-PLAUR (PLAUR) Antibodies
Did you look for something else?